

Grant Cycle 2 Year 6	Project Title	Principal Investigator	Institution
1/08 – 12/08	Prostate Cancer Stem Cells	Norm Greenberg, PhD	FHCRC
1/08 – 12/08	Isotopically Heavy Protein Standards to Calculate Absolute Protein Concentration	Daniel Martin, MD	ISB
1/08 – 12/08	Hormonal and Molecular Effects of Exogenous Dihydrotestosterone on the Prostate	Stephanie Page, MD, PhD	UW
1/08 – 12/08	Inhibition of Angiotensin-2 in CaP Bone and Soft Tissue Tumors in SCID Mice	Robert Vessella, PhD	UW
1/08 – 12/08	Targeted Alpha Therapy for Treatment of Metastatic Prostate Cancer in Bone	Scott Wilbur, PhD	UW
Yr 7			
1/09 – 12/09	Effect of dietary intervention on insulin and IGF-1 receptors in prostate cancer	Anne McTiernan, MD Jonathan Wright, MD	FHCRC
1/09 – 12/09	Novel ultra sensitive DNA-based cancer prostate biomarkers	Jason Bielas, PhD	FHCRC
1/09 – 12/09	Elucidation of novel mechanisms of sulforaphane chemoprevention in a murine model	Joshi Alumkal, MD	OHSU
1/09 – 12/09	Role of PACS-2 in prostate cancer	Gary Thomas, PhD	OHSU
Yr 8			
1/10 – 12/10	Exploring the role of steroid transport genes in prostate cancer progression and response to therapy	Elahe Mostaghel, MD, PhD	FHCRC
1/10 – 12/10	Characterization of microRNAs in urine for diagnosis and prognosis of prostate cancer	Daniel Lin, MD	FHCRC
1/10 – 12/10	Detection of grade 4 prostate cancer in urine of men with low grade cancer biopsies	Martin Gleave, MD Colin Collins, PhD	UBC
1/10 – 12/10	A novel FISH assay to assess the prognostic significance of TMPRSS2-ERG fusion	Min Fang, MD, PhD	FHCRC
1/10 – 12/10	Role of TCA cycle enzymes MDH2-CS in prostate cancer development and chemosensitivity	David Qian, PhD	OHSU